Skip to main navigation
VIR logo

Press Releases

Date Title
5/18/22 Vir Biotechnology Reminds Stockholders of 2022 Annual General Meeting Details
5/5/22 Vir Biotechnology Provides Corporate Update and Reports First Quarter 2022 Financial Results
4/27/22 Vir Biotechnology Announces New Data From the MARCH Hepatitis B Trial, Unveils New Hepatitis D Clinical Program and Highlights Broad Hepatitis Portfolio at Virtual Hepatitis Portfolio R&D Day
4/21/22 Vir Biotechnology to Provide Corporate Update and Report First Quarter 2022 Financial Results on May 5, 2022
4/13/22 Vir Biotechnology to Host a Virtual Hepatitis Portfolio R&D Day
4/6/22 Vir Biotechnology Scientists Named Winners of the BARDA and HHS-Sponsored Pediatric COVID-19 Data Challenge
4/4/22 Vir Biotechnology to Participate in the 21st Annual Needham Healthcare Conference
3/25/22 US Food and Drug Administration Revises Emergency Use Authorization for Sotrovimab Due to Omicron BA.2 Subvariant
3/2/22 Vir Biotechnology to Participate in the 42nd Annual Cowen Healthcare Conference
2/24/22 Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results

Pagination

  • Current page 1
  • Page 2
  • Next page next ›
  • Last page last »
Displaying 1 - 10 of 17
  • Corporate Governance
    • Charters & Governance
    • Leadership
  • Press Releases
  • Events & Presentations
  • Stock Information
    • Stock Quote & Chart
    • Analyst Coverage
  • SEC Filings
  • Investor Resources
    • FAQ
    • Investor Contact
    • Email Alerts
  • Financial Information
    • Quarterly Results
  • About
    • Mission
    • Leadership
  • Science
    • Platforms
    • Literature Archive
  • Pipeline
    • Our Focus
    • Our Collaborators
  • Careers
    • Join Us
    • VIRtues
    • Job Opportunities
  • Contact
  • Investors
    • Corporate Governance
      • Charters & Governance
      • Leadership
    • Press Releases
    • Events & Presentations
    • Stock Information
      • Stock Quote & Chart
      • Analyst Coverage
    • SEC Filings
    • Investor Resources
      • FAQ
      • Investor Contact
      • Email Alerts
    • Financial Information
      • Quarterly Results
  • Print Page
  • Email Alerts
  • RSS Feeds
  • Investor Contact
  • About
    • Mission
    • Leadership
  • Science
    • Platforms
    • Literature Archive
  • Pipeline
    • Our Focus
    • Our Collaborators
  • Careers
    • Join Us
    • VIRtues
    • Job Opportunities
  • Contact
  • Investors
    • Corporate Governance
      • Charters & Governance
      • Leadership
    • Press Releases
    • Events & Presentations
    • Stock Information
      • Stock Quote & Chart
      • Analyst Coverage
    • SEC Filings
    • Investor Resources
      • FAQ
      • Investor Contact
      • Email Alerts
    • Financial Information
      • Quarterly Results

vir logo white

Vir Biotechnology, Inc.
499 Illinois Suite 500
San Francisco, CA 94158
415-906-4324

email: info@vir.bio

  • LinkedIn
  • Twitter
©  Vir Biotechnology All rights reserved.
  • Privacy Policy
  • Terms of Use